Lates News

date
11/05/2025
According to an AI alert from Meijing, on May 8th, Southwest Securities released a research report and gave a buy rating to KQEN Biotechnology (688526.SH). The reasons for the rating include: 1) Downstream cycle fluctuations are putting pressure on performance, but improvement is expected in Q4 of 2024; 2) Research and development innovation driving growth, with high expectations for the multiple vaccine pipeline; 3) Improvements in funding for breeding enterprises are boosting the animal health sector. (Daily Economic News)
Latest